1 / 25

State and Metropolitan-Area Based Amyotrophic Lateral Sclerosis (ALS) Surveillance

State and Metropolitan-Area Based Amyotrophic Lateral Sclerosis (ALS) Surveillance. Paul English Susan Paulukonis Jhaqueline Valle March 21, 2012. Partnership with ATSDR & McKing Consulting Corporation ATSDR funded

adanna
Download Presentation

State and Metropolitan-Area Based Amyotrophic Lateral Sclerosis (ALS) Surveillance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. State and Metropolitan-Area Based Amyotrophic Lateral Sclerosis (ALS) Surveillance Paul English Susan Paulukonis Jhaqueline Valle March 21, 2012

  2. Partnership with ATSDR & McKing Consulting Corporation • ATSDR funded • Implement a metropolitan area-based ALS surveillance project in Los Angeles and the San Francisco Bay Area(18month project)

  3. History of ALS

  4. What is ALS? • Amyotrophic Lateral Sclerosis (ALS), often called ‘Lou Gehrig’s disease.’ • Motor neuron disease, progressive loss of physical functioning • First identified in 1869 by French neurologist Jean-Martin Charcot • Cause not known in most cases, • Small proportion (10%) of cases are genetically linked • Environmental and occupational associations are being investigated

  5. What is ALS? • Incidence: 1 - 3 per 100,000 person-years in industrialized nations (sources differ) • Typical age of onset: 40 to 60 years • Average life expectancy from time of diagnosis: median is 24 months. 90% of cases die within 5 to 8 years of diagnosis

  6. Why do in context of tracking? • Building surveillance capacity/experience with registry methodologies • Opportunity to track historic addresses from participants with new methods • Will be able to keep data; use for future case/control studies • Aligns with national funding goals for Tracking and ALS surveillance

  7. Only 5-10% of ALS due to inherited genetic mutations Trauma Increased risk in Italian soccer players Occupational Exposure to Pesticides (RR=3.6, 95% C.I. 1.2, 10.5) Bonvicini 2010 ALS and Environment

  8. ALS and Environment • Guam: 100 X frequency ALS • BMAA amino acid found in seeds of the cycad Cycasmicronesica in food chain (fruit bat) • BMAA is found in brain tissue of ALS victims • BMAA produced by Cyanobacteria • BMAA found in contaminated shellfish, drinking water • Cyanobacterial blooms (blue-green algae) are increasing due to climate change

  9. National ALS Surveillance/Registry

  10. Early ALS Surveillance • Agency for Toxic Substances and Disease Registry (ATSDR) funded IL, MA, MO, OH, OR, TX • determine the prevalence of ALS in defined geographic areas (2002-2006) • Inpatient data, outpatient data, self-referrals, nursing home admissions and death certificates • Case ascertainment relatively low • Medical records not always accessible • potential source of bias

  11. ALS Registry • Conclusion: create a national ALS registry to more accurately determine incidence/prevalence • National ALS Registry mandated by Congress. • Registry identifies cases from two data sources: • administrative data (CMS, VHA, and VBA) • self-registration through a secure web portal • Non-traditional approach to be validated with more conventional surveillance technique • case reports to health departments

  12. State and Metropolitan-Area Surveillance Projects • Objectives: • Use project data to evaluate the completeness of ATSDR’s National ALS Registry • Obtain reliable and timely information on the incidence and prevalence of ALS and better describe the demographic characteristics (age, race, sex, and geographic location)

  13. Participating Sites

  14. Site Selection • Sites selected to over-represent ethnic and racial minorities • Sites of sufficient size to contribute >100 cases each to the surveillance project • Los Angeles County expected cases: 785 • San Francisco Bay Area expected cases: 360

  15. National ALS Registry vs. State/Metro ALS Surveillance

  16. Los Angeles & San Francisco Bay Area ALS Surveillance Project

  17. Project Implementation • California counties searched for cases: • Los Angeles and • San Francisco Bay Area • Alameda • Contra Costa • San Francisco • San Mateo • Solano

  18. Project Implementation • Outreach • Compensation/Training • Data Collection • Case Ascertainment • Case Re-abstraction • Case Verification • Missing Cases • Data Analysis/Final Report

  19. Project Implementation Outreach • Approach all neurologists in target counties and surrounding areas. • Mailings, Calls, Office Visits, Professional Meetings, etc.. • Ongoing Compensation/Training • Participating neurology practices are compensated per case • Training provided to staff at participating practices as needed

  20. Public Health Surveillance vs. Research • Doctors can release private health information with identifiers without obtaining permission from the person with ALS • Public health surveillance is a permitted but not required release under HIPAA • A signed consent form and a signed HIPAA authorization form are not needed for this project

  21. Project Implementation Data Collection-Case Ascertainment • Collection of data on diagnosed/treated cases of ALS, 2009-2011 • Office staff abstract medical records to provide data Data Collection - Re-Abstraction • Subset of records submitted are reviewed/validated for quality check Data Collection - Validation • Validated records are reviewed by project neurologist to assure correct diagnosis Missing Cases • Final records are compared with hospital discharge and vital records (death certificate) data to find missed cases

  22. Project Implementation Analysis • Descriptive analysis of cases (age, sex, race/ethnicity, birthplace, etc.) Final Report • Methods used • Problems/Solutions • Summary of data analysis

  23. Timeline • January, 2012: Project period begins • May, 2012: Begin data collection • April, 2013: Data collection complete • June, 2013: Analysis of data • July, 2013: Final report/End of project

  24. Organizational Endorsement Current Endorsements • ATSDR • ALS Association (ALSA) National • ALSA Golden West Chapter Approaching for Endorsement: • American Academy of Neurology • CA Neurological Association • San Francisco Neurological Society • Los Angeles Neurological Society :

  25. Questions for TIAG • Thoughts on use of Metro Area ALS Surveillance data? Funding for additional work? • Contacts in Los Angeles and/or SF Bay Area neurology communities?

More Related